CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone CapitalInitial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone CapitalInitial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury StrategyMELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing treatments for recurring and metastatic cancer, announced its fiscal year-end update following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025. The reporting period concluded on June 30, 2025.
